End-of-day quote
Shenzhen S.E.
06:00:00 2024-07-14 pm EDT
5-day change
1st Jan Change
3.88
CNY
-1.77%
+0.78%
-42.52%
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 07:43 am EDT
Shanxi Zhendong Pharmaceutical Co.,Ltd reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 4,052.41 million compared to CNY 3,372.46 million a year ago. Revenue was CNY 4,052.41 million compared to CNY 3,372.46 million a year ago. Net income was CNY 323.01 million compared to CNY 207 million a year ago. Basic earnings per share from continuing operations was CNY 0.3144 compared to CNY 0.2015 a year ago. Diluted earnings per share from continuing operations was CNY 0.3144 compared to CNY 0.2015 a year ago.
Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board Appointments
May. 20
CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.
May. 06
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback announced on February 6, 2024, has closed with 22,174,904 shares, representing 2.16% for CNY 102.76 million.
Apr. 29
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 22
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 22
CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.
Apr. 03
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd agreed to acquire additional 53.985% stake in Guangdong Longchuangji Pharmaceutical Co., Ltd. from Guangdong Qiangji Pharmaceutical Co., Ltd.
Mar. 07
CI
Guangdong Longchuangji Pharmaceutical Co., Ltd. announced that it has received CNY 30 million in funding from Shanxi Zhendong Pharmaceutical Co.,Ltd
Mar. 06
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 200 million worth of its shares.
Feb. 06
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
Feb. 05
CI
Guangdong Longchuangji Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Shanxi Zhendong Pharmaceutical Co.,Ltd
Jan. 18
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-22
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-30
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-24
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-24
CI
FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. completed the aquistion of Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd.
22-10-27
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-25
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd(XSEC:300158) added to S&P Global BMI Index
22-09-19
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-21
CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd.
22-07-14
CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. signed a share transfer agreement to acquire a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd. for approximately CNY 340 million.
22-06-19
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-21
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
22-02-25
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-27
CI
FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd for CNY 5.8 billion.
21-08-17
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Shanxi Zhendong Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs, chemical raw materials and preparations. The Company's main products include anti-tumor series, cardiovascular and cerebrovascular series, anti-infection series, digestive system series, vitamin nutrition series, respiratory system series, antipyretic analgesic series and nervous system series. The Company is also involved in the cultivation of medicinal herbs, as well as the wholesale and retail of pharmaceutical products. The Company distributes its products in domestic market, with North China market as its main market.
More about the company
1st Jan change
Capi.
-42.52% 550M +63.05% 856B +39.06% 631B -4.78% 359B +17.52% 325B +8.43% 297B +13.60% 244B +5.44% 234B +16.58% 226B +14.63% 177B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1